PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16863464-0	2006	Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.	Vitamin K	41-50	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	16-22	
16863464-3	2006	CYP2C9 makes a very important contribution to metabolism of vitamin K antagonist anticoagulants, and is the main oxidising enzyme for S-warfarin and S-acenocoumarol as well as contributing to phenprocoumon metabolism.	Vitamin K	60-69	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6	
16863464-6	2006	Although CYP2C9 genotype is clearly a predictor of vitamin K antagonist dose requirement, especially in Caucasian populations in whom variant alleles are common, a number of recent studies have shown that age, genotype for the gene encoding the target gene vitamin K epoxide reductase and concomitant drugs are equally important factors in determining dose.	Vitamin K	51-60	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	9-15